The chairman of the Kentucky Racing Commission says an investigation of a personal services contract awarded for a review of drug research is an attack on the racing commission and Thoroughbred industry in the state.
The first joint meeting of the boards of the Thoroughbred Racing Associations and Harness Tracks of America was considered a success, but whether the two organizations continue to meet jointly on a regular basis remains to be seen.
Officials said the classification of erythropoeitin -- the blood-doping agent commonly known as EPO -- as a prohibited practice has curbed its use in some jurisdictions but a definitive test for the substance is a must if any regulation is to have teeth.
Kentucky officials will consider regulations for use of shock-wave therapy in racehorses and also whether money for equine drug research should be spent on establishing threshold levels and withdrawal times for permitted medications.
Two bills that would permit officials in Kentucky to spend money on equine drug research out of state were withdrawn from consideration in the state House of Representatives.
Antibodies for erythropoeitin, a blood-doping substance commonly known as EPO, were found in six racehorses at Sam Houston Race Park, the Dallas Morning News reported Feb. 18.
Aqueduct-based trainer Gary Contessa is awaiting his fate on a slew of ephedra positives that have sidetracked his operation.
The Racing Medication and Testing Consortium has elected officers, chosen an executive director, and put the finishing touches on few sections of its proposed model policy for medication and drug testing. Breeders' Cup president D.G. Van Clief Jr. was elected chairman.
The Racing Medication and Testing Consortium is scheduled to meet Feb. 4 in Atlanta, Ga., to hammer out details of its structure and further develop its policy statement.
The Kentucky Racing Commission has decided to form a committee to explore the testing of horses on days they're not scheduled to race. The decision stems from an earlier classification of erythropoeitin and the process of blood-doping as a prohibited practice.
Be My Royal, winner of the one the biggest races of the National Hunt season to date, faces disqualification in connection with a rash of positive drug tests for traces of morphine in British and Irish races due to contaminated feed.
The Kentucky Equine Drug Council will ask the Kentucky Racing Commission Jan. 15 to form a committee to tackle the complicated and controversial issue of out-of-competition testing.
The Texas Racing Commission has renewed its drug-testing contract with Texas Veterinary Medical Diagnostic Laboratory, and also approved some changes in the racing schedule at Manor Downs for 2003.
The Racehorse Medication and Testing Consortium formed earlier this year has incorporated as a charitable organization and issued its goals and objectives, one of which has been broadened to include the auction and training aspects of the Thoroughbred business.
The National Horsemen's Benevolent and Protective Association is prepared to release a revised proposal for a national policy on drug testing and therapeutic medication. The document deals with Class 1, 2, 3, and 4 medications, as well as prohibited practices.
The Thoroughbred Owners and Breeders Association, quite active on the racehorse medication front for the past few years, is advocating a plan to implement "super tests" for all graded stakes in the United States.
The Racing Medication and Testing Consortium is moving forward with a national policy statement and plans to incorporate.
Industry representatives in West Virginia met by teleconference Oct. 15 to devise emergency rules to govern use of adjunct bleeder medications and to ban the practice of blood-doping.
With no opposition in sight, the Kentucky Racing Commission on Sept. 24 officially revised its Thoroughbred race-day medication policy to reduce the number of permitted substances from 16 to five.
The Maryland Racing Commission has reduced the penalties of two trainers who had been dealt lengthy suspensions after their horses raced at Pimlico Race Course with an illegal drug in their systems.
The Kentucky Racing Commission, apparently at the urging of the state Equine Drug Council, has hired Dr. Richard Sams of Ohio State University to serve as a consultant on medication and drug-testing issues.
The chairman of the Kentucky Racing Commission said Sept. 13 he hopes a revised race-day medication policy for the Bluegrass state becomes a model for the rest of the country as it pushes toward uniformity in racehorse medication and drug testing.
Horsemen, veterinarians, racing officials, and regulators in Kentucky have been working behind the scenes to develop a new medication policy for the state that figures to greatly influence the debate over a uniform medication policy for the United States.
The Florida Division of Pari-Mutuel Wagering in August filed an administrative complaint against trainer Henry Collazo, alleging that a horse he ran at Calder Race Course tested positive for a derivative of morphine. The case has again put Florida's zero-tolerance policy under scrutiny.
Three trainers have been suspended and fined in New York for drug positives, two for lidocaine, a topical anesthetic that produced two positives in Kentucky earlier this year.
As the Thoroughbred industry embarks on a national campaign to encourage more investment in racehorses, the chairman of the Thoroughbred Owners and Breeders Association has issued a plea for uniformity in medication to help the sport in a number of areas.
In the second round of "super tests" performed under the guidance of the National Thoroughbred Racing Association Racing Integrity and Drug Testing Task Force, there were no new positives for Class 1, 2, and 3 medications, according to a final report recently released. There were, however, 454 confirmations for therapeutic drugs.
The Pennsylvania State Horse Racing Commission has issued an advisory that erythropoietin, or EPO, and other blood-doping substances and procedures are not permitted in the state.
A July 2 panel discussion on racetrack medication and the "reality of perception" led to allegations of medication abuse, racing surfaces that damage horses, and a regulatory system that hinders progress.
The California Horse Racing Board begins filming for two videos it hopes will take the mystery out of post-race testing while assuring fans and horsemen of the sport's integrity.
The Kentucky Racing Commission said June 25 it would consider at its next meeting in September a motion to make the possession or use of erythropoietin, known as EPO, a prohibited practice.
The Kentucky Racing Commission on June 25 upheld a hearing officer's recommendation that trainer William Deaton be suspended 150 days because one of his horses tested positive for Prozac this winter at Turfway Park.
The Kentucky Racing Commission on June 25 will rule on an appeal of a 150-day suspension by trainer William Deaton concerning a positive test for Prozac in one of his horses at the Turfway Park meet earlier this year.
The National Thoroughbred Racing Association has formed a "working group" to develop a coordinated industry response for the one-year anniversary of the Sept. 11 terrorist attacks on the United States.
Kent Stirling, executive director of the Florida Horsemen's Benevolent and Protective Association, and Dr. Rick Arthur, a vice president of Oak Tree Racing Association, have been named to the National Thoroughbred Racing Association's Racing Integrity and Drug Testing Task Force.
Trainers Ben Cecil and Howard Zucker were slapped with fines by the California Horse Racing Board for positive drug tests produced from races at Del Mar last summer, it was announced May 30.
The board of directors of the Kentucky Thoroughbred Association has formally stated its "dissatisfaction" with current medication policies in the Bluegrass State.
As the Racing Medication and Testing Consortium continues its march toward uniformity in Thoroughbred racing, battle lines are being formed by other groups that believe a furosemide-only policy on race days is too extreme.
The newly christened Racing Medication and Testing Consortium said May 1 it has formed three task forces to focus on developing an organizational and business plan, scientific research priorities, and a model medication policy.
Representatives of 15 Thoroughbred, Quarter Horse, and Standardbred organizations will meet May 1 at a by-invitation-only meeting to implementation of recommendations on drug-testing, medication, security, and enforcement.
While the Thoroughbred industry makes an aggressive push toward unification on the issue of drug testing and medication, two organizations involved in the regulation of racing -- the Association of Racing Commissioners International and the National Association of Pari-Mutuel Regulators -- continue to go their separate ways.
The results of a survey of members of the Kentucky Horsemen's Benevolent and Protective Association indicate that more than 90% favor the current medication policies in place in the Bluegrass State.
Uniformity in equine drug-testing and medication use won't come easy if comments made by panelists at the University of Florida's Equine Medical Symposium are any indication. If anything, the March 15 discussion revealed splits within the racing industry and brought up the question as to whether medication is really the root of the industry's problems.
As the National Thoroughbred Racing Association Racing Integrity and Drug Testing Task Force prepared to release the results of round two of its super-testing program, the University of Florida appropriately kicked off its first Equine Medical Symposium March 14 with discussion on some therapeutic medications.
Jim Gallagher, executive director of the National Thoroughbred Racing Association Racing Integrity and Drug Testing Task Force, will leave the organization March 28 to take the position of vice president of pari-mutuel operations for the New York Racing Association.
As the National Thoroughbred Racing Association Racing Integrity and Drug Testing Task Force prepared for its March 12 meeting, some racetrack veterinarians moved closer to forming their own organization.
Setting a national policy for racehorse medication is a vital step for the sport's long-term health, a top industry executive told the 2002 Harness Racing Congress in Las Vegas, Nev., Feb. 20.
The Kentucky Horsemen's Benevolent and Protective Association is polling horsemen to get their opinions on the state's medication policies, which include a ban on all Class 1, 2, and 3 drugs within 48 hours of a race, and use of anti-inflammatory anti-bleeding medications on race day.
A panel discussion on medication use and regulations in the pari-mutuel industry will be part of an equine medical symposium hosted by the University of Florida College of Veterinary Medicine March 14-15 in Hollywood Beach, Fla.
In the wake of a Jan. 28 teleconference to discuss plans for a national medication policy, organizers and the National Horsemen's Benevolent and Protective Association continue to negotiate on a representation issue.
Most Popular Stories
- Katie's Kiss First Winner for Kantharos
- No Lasix for Social Inclusion in Haskell
- Samraat Headed Back to Saratoga After Surgery
- Taghrooda Flies to King George Triumph
- Trainer, Jock Team for South African Double
- Keeneland's Historical Racing Plans Delayed
- Dance With Fate's Exercise Rider Has Surgery
- Irish Surf Runs Away in Cougar II Marathon
- Dance With Fate Euthanized After Accident
- Whitney Card's Grade I Races Taking Shape